Clinical Trials for Molecular Targeted Agents / Immunotherapy /

100 Open Trials

Trial Type &
Disease
Protocol No. &
Open Date
Summary
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMEL12117
02/18/2013
A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy
Molecular Targeted Agents / Immunotherapy / Biologics
Neuroblastoma (Pediatrics);
Pediatric Solid Tumors
VICCPED12112
01/04/2013
NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic;
Leukemia;
Multiple Myeloma
VICCBMT12104
02/04/2014
Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
VICCTHN1326
01/10/2014
A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study Comparing The Efficacy and Safety of Clonidine Lauriad 50 ig and 100 ig Mucoadhesive Buccal Tablet (MBT) Applied Once Daily to Those of Placebo in the Prevention and Treatment of Chemoradiation Therapy Induced Oral Mucositis in Patients with Head and Neck Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Pediatric Solid Tumors
COGACCL0922
02/20/2013
SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
PRECOGHEM0901
12/04/2012
Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia;
Myelodysplastic Syndrome
VICCBMT1218
09/04/2012
A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors
Molecular Targeted Agents / Immunotherapy / Biologics
Other Skin
VICCNCPED1210
02/20/2012
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients with Dystrophic Epidermolysis Bullosa.
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
VICCPED0921
05/01/2009
Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD.
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBRE1390
04/23/2014
A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone-Receptor Positive, HER2-negative, Advanced Breast Cancer who Received no Prior Therapy for Advanced Disease
Molecular Targeted Agents / Immunotherapy / Biologics
Esophageal;
Gastric/Gastroesophageal;
Lung;
Non Small Cell;
Pancreatic
VICCPHI1360
04/22/2014
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors
Molecular Targeted Agents / Immunotherapy / Biologics
Breast;
Colon;
Lung;
Ovarian;
Pancreatic;
Prostate;
Rectal
VICCPHI1394
04/17/2014
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Pediatric Leukemia;
Pediatric Lymphoma
VICCPED1365
04/16/2014
T2011-002: A Phase I Study of 5-Azacytidine in Combination with Chemotherapy for Children with Relapsed or Refractory ALL or AML
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
VICCHEM13110
04/11/2014
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
VICCHEM13106
04/09/2014
A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior Multi-Agent Chemotherapy Regimen in Subjects Who Are Not Candidates for ASCT
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
VICCHEM13105
04/09/2014
A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic
VICCHEM1274
03/31/2014
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMELP1388
03/24/2014
A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors.
Molecular Targeted Agents / Immunotherapy / Biologics
Breast - Female
VICCBREP1363
03/21/2014
A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic
VICCPED1354
03/17/2014
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Molecular Targeted Agents / Immunotherapy / Biologics
Multiple Myeloma
VICCHEM1377
03/14/2014
A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia;
Lymphoma;
Multiple Myeloma
VICCHEM1392
03/12/2014
A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies
Molecular Targeted Agents / Immunotherapy / Biologics
Lung;
Non Small Cell
VICCTHN12106
03/12/2014
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
Molecular Targeted Agents / Immunotherapy / BiologicsVICCPHI1364
03/07/2014
A Phase Ib, Open-Label Study of Oral BGJ398 in Combination with Oral BYL719 in Adult Patients with Select Advanced Solid Tumors
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoid Leukemia;
Myeloid and Monocytic Leukemia
VICCPED1355
03/05/2014
Multi-Center, Open-Label Ranodomized Study of Single or Double Myleoablative Cord Blood Transplantation With or Without Infusion of Off-the-Shelf Ex Vivo Expanded Cyropreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies
Molecular Targeted Agents / Immunotherapy / Biologics
Lung
VICCTHN1379
02/21/2014
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB/IV) (SELECT-1)
Molecular Targeted Agents / Immunotherapy / BiologicsVICCPHI1342
02/11/2014
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
Molecular Targeted Agents / Immunotherapy / Biologics
Bladder
VICCURO1367
01/27/2014
An Integrated Phase II/III Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with Non-Muscle Invasive Bladder Carcinoma in Situ Disease ("NMIBCis", Meaning CIS and CIS with Ta and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy
Molecular Targeted Agents / Immunotherapy / Biologics
Colon;
Esophageal;
Pancreatic
VICCBMT1381
01/23/2014
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Orbec? (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by Graft vs Host Disease (GVHD) in Patients with Chronic GI GVHD
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic;
Leukemia
VICCHEM1346
01/21/2014
A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
ECOGTHNR1216
01/10/2014
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Molecular Targeted Agents / Immunotherapy / Biologics
Pancreatic
VICCGI1370
12/30/2013
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
VICCHEM1336
12/09/2013
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy
Molecular Targeted Agents / Immunotherapy / Biologics
Breast;
Gastric/Gastroesophageal;
Lung;
Pancreatic
VICCPHI1359
12/03/2013
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Molecular Targeted Agents / Immunotherapy / Biologics
Breast - Female;
Breast - Male
ECOGBRES1207
10/31/2013
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
Molecular Targeted Agents / Immunotherapy / Biologics
Lung
VICCTHNP1353
10/30/2013
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMEL1351
10/17/2013
A Phase 2 study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
VICCTHN1340
10/14/2013
A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
VICCHEM1323
10/03/2013
A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib
Molecular Targeted Agents / Immunotherapy / BiologicsVICCPHI1255
09/28/2013
Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMELP1325
09/25/2013
A Phase IB/II, Multicenter, Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF mutant melanoma
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBRE1287
09/23/2013
A Phase Ib/II Trial of GDC-0941 (a PI3K inhibitor) in combination with Cisplatin in patients with androgen receptor negative Triple Negative Metastatic Breast Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Thyroid
VICCTHN1318
09/19/2013
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Breast;
Melanoma
VICCPHI1333
09/18/2013
A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCPHI1328
09/05/2013
A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination with Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma
Molecular Targeted Agents / Immunotherapy / Biologics
Colon;
Rectal
ECOGGIS0820
09/03/2013
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
VICCTHN1257
08/30/2013
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy followed by Standard Chemoradiation/Afatinib in HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBRE1320
08/16/2013
A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Multiple Myeloma
VICCHEM1319
08/07/2013
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
Molecular Targeted Agents / Immunotherapy / Biologics
Esophageal;
Gastric/Gastroesophageal
VICCGI1306
07/11/2013
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Positive Carinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia;
Lymphoma;
Pediatric Leukemia;
Pediatric Lymphoma
VICCPED1338
06/27/2013
T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies
Molecular Targeted Agents / Immunotherapy / Biologics
Colon;
Rectum
VICCPHI1314
06/25/2013
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Neuroblastoma (Pediatrics)
COGANBL12P1
06/05/2013
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
VICCHEM1284
06/05/2013
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBRE1304
06/04/2013
A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases
Molecular Targeted Agents / Immunotherapy / Biologics
Neuroendocrine;
Pancreatic
VICCGI1250
04/09/2013
A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)
Molecular Targeted Agents / Immunotherapy / Biologics
Multiple Myeloma
VICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBREP12116
03/25/2013
An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Prostate
VICCURO1260
03/19/2013
A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy
Molecular Targeted Agents / Immunotherapy / Biologics
Esophageal
VICCGI1211
03/08/2013
Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Esophageal
ECOGGIR1010
02/28/2013
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Molecular Targeted Agents / Immunotherapy / Biologics
Gastric/Gastroesophageal
VICCGI1283
02/14/2013
A Randomized, Multicenter, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel or Paclitaxel) in Patients with Previously Treated Locally Advanced or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCBRE1280
02/07/2013
A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Which Progressed On or After Aromatase Inhibitor Treatment
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMEL1263
01/08/2013
Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic
VICCHEM1180
01/04/2013
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 X10 9/L to 100 X10 9/L
Molecular Targeted Agents / Immunotherapy / Biologics
Lung;
Small Cell
VICCTHN1189
12/14/2012
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCMEL1256
12/06/2012
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence
Molecular Targeted Agents / Immunotherapy / Biologics
Melanoma
VICCPHI1231
11/19/2012
Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma
Molecular Targeted Agents / Immunotherapy / Biologics
Lung;
Non Small Cell
VICCTHN1242
10/24/2012
A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
VICCPHI1248
10/12/2012
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Neuro-Oncology
VICCNEU1216
10/02/2012
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
ECOGTHNR1016
09/25/2012
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
ECOGTHNR0920
09/12/2012
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
VICCHEM1146
08/14/2012
Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma
Molecular Targeted Agents / Immunotherapy / Biologics
Neuroblastoma (Pediatrics);
Pediatric Solid Tumors
VICCPED1249
08/06/2012
An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Molecular Targeted Agents / Immunotherapy / Biologics
Pancreatic
VICCGI1173
07/31/2012
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma
Molecular Targeted Agents / Immunotherapy / BiologicsVICCTHN1244
07/25/2012
Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia;
Pediatric Leukemia
VICCPED1186
06/11/2012
CA180-372 / AALL1122 - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66, 971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Molecular Targeted Agents / Immunotherapy / Biologics
Adrenocortical;
Bladder;
Breast;
Cervical;
Colon;
Dermatologic;
Esophageal;
GIST;
Gastric/Gastroesophageal;
Gynecologic;
Head/Neck;
Kidney (Renal Cell);
Liver;
Lung;
Multiple Myeloma;
Neuroendocrine;
Ovarian;
Pancreatic;
Prostate;
Rectal;
Sarcoma;
Small Cell;
Uterine
VICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic
VICCBMT1148
05/11/2012
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation (Consortium)
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
CTSUNSABPBREB-47-M
04/26/2012
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 
Molecular Targeted Agents / Immunotherapy / Biologics
Breast
CTSUBRENB-43-M
04/26/2012
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
ECOGHEME2906
01/20/2012
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
VICCBMT1129
11/17/2011
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft vs Host Disease
Molecular Targeted Agents / Immunotherapy / Biologics
Leukemia
VICCHEM1096
10/24/2011
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Molecular Targeted Agents / Immunotherapy / Biologics
Neuro-Oncology
COGACNS0821
10/08/2011
ACNS0821 - Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Molecular Targeted Agents / Immunotherapy / Biologics
Lung;
Non Small Cell
ECOGTHNE5508
06/29/2011
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Molecular Targeted Agents / Immunotherapy / Biologics
Lymphoma
ECOGHEME2408
05/10/2011
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Molecular Targeted Agents / Immunotherapy / Biologics
Neuroblastoma (Pediatrics);
Pediatric Lymphoma
COGADVL0912
04/05/2011
PH 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-MET, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Molecular Targeted Agents / Immunotherapy / Biologics
Neuro-Oncology
VICCRAD1060
02/15/2011
A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients with 1-4 Brain Metastases
Molecular Targeted Agents / Immunotherapy / Biologics
Non Small Cell
ECOGTHO5508-M
02/09/2011
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Molecular Targeted Agents / Immunotherapy / BiologicsVICCPHI1065
02/01/2011
A phase IA, multicenter, open-label dose escalation study of oral BYL719, in adult patients with advanced solid malignancies, whose tumors have an alteration of the PIK3CA gene
Molecular Targeted Agents / Immunotherapy / Biologics
Hematologic/Non-transplant
VICCPHI1040
12/21/2010
A Phase I Study to Evaluate the Safety and Clinical Activity of WT1-A10+AS01B Antigen Specific Cancer Immunotherapeutic in Adult Patients with WT1-Positive Acute Myeloid Leukemia in Partial Remission with Incomplete Blood Count Recovery Post-Induction Therapy
Molecular Targeted Agents / Immunotherapy / Biologics
Liver
CTSUGIC80802-M
12/07/2010
Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Molecular Targeted Agents / Immunotherapy / Biologics
Lung
CTSUTHOC30607-M
02/17/2010
ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
GIST
VICCPHI0958
02/05/2010
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
ECOGHNE1305
03/04/2009
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
Molecular Targeted Agents / Immunotherapy / Biologics
Head/Neck
ECOGHNE1305-M
02/11/2009
A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
Molecular Targeted Agents / Immunotherapy / Biologics
Non Small Cell
ECOGTHOE1505-M
07/27/2007
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)
Molecular Targeted Agents / Immunotherapy / Biologics
Benign Hematologic
VICCNCPED10101
12/28/2006
Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine with or without Campath

Back to Find By Treatment

You do not have JavaScript enabled. This site works better with JavaScript turned on.